Treatment of Leukemia
Leukemia is a cancer of blood-forming tissues that disrupts normal blood cell production. It is classified by speed of progression (acute/chronic) and cell type (lymphocytic/myeloid), causing fatigue, bleeding, and infections.
Managing Leukemia effectively requires a combination of medical treatment, lifestyle modification, and regular monitoring. With a structured management plan, most people with Leukemia can maintain a good quality of life and prevent serious complications.
First-Line Treatment Principles
- ✓Multidisciplinary team (MDT) approach: oncology, surgery, radiotherapy, pathology, palliative care
- ✓Stage-appropriate intent: curative vs. palliative — informs treatment intensity and goals
- ✓Systemic therapy: chemotherapy, targeted therapy, immunotherapy (checkpoint inhibitors), hormone therapy
- ✓Surgical resection: primary curative approach for solid tumours when localised
- ✓Radiotherapy: definitive, adjuvant, or palliative depending on tumour type and stage
What to Do Now
- Learn your personal risk factors for Leukemia (family history, age, lifestyle)
- Attend regular health check-ups and screening tests appropriate for your age and risk
- Track new or changing symptoms, especially those associated with Leukemia
- Use our AI symptom checker to assess whether your symptoms fit an early Leukemia pattern
- Discuss preventive strategies and early monitoring with your GP
- Build a personalised management plan with your GP or specialist
- Adhere consistently to prescribed medications — do not stop without medical advice
- Adopt a Leukemia-appropriate diet (anti-inflammatory, low-glycaemic, or disease-specific)
Medications Used in Leukemia
Imatinib is a targeted cancer therapy that blocks specific molecular pathways driving tumor growth and proliferation.
Osimertinib is a targeted cancer therapy that blocks specific molecular pathways driving tumor growth and proliferation.
Ibrutinib is a targeted cancer therapy that blocks specific molecular pathways driving tumor growth and proliferation.
Sunitinib is a targeted cancer therapy that blocks specific molecular pathways driving tumor growth and proliferation.
Erlotinib is a targeted cancer therapy that blocks specific molecular pathways driving tumor growth and proliferation.
Gefitinib is a targeted cancer therapy that blocks specific molecular pathways driving tumor growth and proliferation.
Venetoclax is a targeted cancer therapy that blocks specific molecular pathways driving tumor growth and proliferation.
Alectinib is a targeted cancer therapy that blocks specific molecular pathways driving tumor growth and proliferation.
Non-Pharmacological Management
- •Nutritional support: maintain weight and muscle mass; dietitian involvement
- •Physiotherapy and exercise oncology: reduced fatigue, improved outcomes
- •Psychological support: validated cancer-specific interventions (CBT, supportive psychotherapy)
- •Smoking cessation and alcohol reduction: reduces treatment toxicity and second primary cancers
- •Palliative care integration from diagnosis: symptom management, advance care planning
- •Fertility preservation: discuss before gonadotoxic therapy in reproductive age patients
- •Sun protection post-treatment: radiation-sensitised skin; immunosuppressed skin cancer risk
Treatment Goals
Monitoring Parameters
- ◆Tumour markers: PSA (prostate), CA-125 (ovarian), CEA (colorectal), AFP (liver) — at defined intervals
- ◆Imaging: CT/MRI/PET per tumour-specific response criteria (RECIST)
- ◆FBC: myelosuppression monitoring during chemotherapy — weekly during active treatment
- ◆Cardiotoxicity: LVEF monitoring with anthracyclines and trastuzumab (echo before, during, after)
- ◆Renal and hepatic function: before each chemotherapy cycle; drug dose adjustments
- ◆Peripheral neuropathy grading: platinum and taxane-based regimens
Red Flags — When to Escalate
- ⚠Any of the characteristic symptoms of Leukemia — even mild — in a high-risk individual
- ⚠Progressive worsening of early warning signs over weeks
- ⚠Laboratory abnormalities (e.g., blood sugar, inflammatory markers) without full symptoms
- ⚠Unexplained weight loss, night sweats, or fatigue persisting >2 weeks
- ⚠Strong family history of Leukemia combined with new relevant symptoms
- ⚠Sudden worsening of Leukemia symptoms despite established treatment
Escalation Criteria
- →Febrile neutropenia: broad-spectrum IV antibiotics within 1 hour of presentation; emergency
- →Progressive disease on first-line treatment → second-line regimen; clinical trial consideration
- →Oncological emergencies: spinal cord compression, SVC syndrome, tumour lysis syndrome → urgent oncology review
- →Deteriorating performance status → reassess treatment goals; palliative focus
Special Populations
Clinical Insights
Compare With Similar Conditions
Not sure about your symptoms?
Our AI Symptom Checker analyses your symptoms and suggests the most likely diagnoses — including relevant treatment pathways.
Use AI Symptom Checker →